» Articles » PMID: 10995013

Biological Effects of Stroma-derived Factor-1 Alpha on Normal and CML CD34+ Haemopoietic Cells

Overview
Journal Leukemia
Specialties Hematology
Oncology
Date 2000 Sep 20
PMID 10995013
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

We compared the biological effects of the CXC chemokine SDF-1alpha on immunomagnetically purified CD34+ cells isolated from human normal bone marrow (NBM), leukapheresis products (LP) and patients with chronic myeloid leukaemia (CML). LP CD34+ cells showed a significantly stronger migration response to SDF-1alpha (100 ng/ml) than CD34+ cells isolated from the peripheral blood (PB) of CML patients (P < 0.05). The chemotactic response to SDF-1alpha was also reduced in CML BM CD34+ cells in comparison to NBM CD34+ cells but the observed differences were not statistically significant. In analogy to normal CD34+ cells circulating CML PB CD34+ cells were less responsive to SDF-1alpha than their BM counterparts (P < 0.05). Furthermore, SDF-1alpha elicited similar concentration-dependent growth suppressive effects on normal and CML CD34+ cells (P > 0.05) in colony-forming cell assays. We then demonstrated that SDF-1alpha triggers intracellular calcium increases in CD34+ cells and there were no differences in the time course and dose response characteristics of normal and CML CD34+ cells. The reduced migration response to SDF-1alpha in CML CD34+ cells was not due to a down-regulation of the SDF-1alpha receptor CXCR-4 as flow cytometric analysis revealed similar CXCR-4 expression levels on NBM, LP, CML PB and CML BM CD34+ cells (P > 0.05). Finally, no differences in the modulation of CXCR-4 levels in response to SDF-1alpha and serum were observed in CML and normal CD34+ cells. Our data suggest that the impaired chemotactic response of CML CD34+ cells to SDF-1alpha is not caused by a lack or complete uncoupling of CXCR-4, but may be due to an intracellular signalling defect downstream of the receptor.

Citing Articles

The underestimated role of basophils in Ph chronic myeloid leukaemia.

Valent P, Horny H, Arock M Eur J Clin Invest. 2018; 48(10):e13000.

PMID: 30019447 PMC: 6175372. DOI: 10.1111/eci.13000.


Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph chronic myeloid leukemia.

Willmann M, Sadovnik I, Eisenwort G, Entner M, Bernthaler T, Stefanzl G Exp Hematol. 2017; 57:50-59.e6.

PMID: 29031704 PMC: 7115814. DOI: 10.1016/j.exphem.2017.09.012.


Chemokines as a Conductor of Bone Marrow Microenvironment in Chronic Myeloid Leukemia.

Mukaida N, Tanabe Y, Baba T Int J Mol Sci. 2017; 18(8).

PMID: 28829353 PMC: 5578209. DOI: 10.3390/ijms18081824.


Expression of CD25 on leukemic stem cells in BCR-ABL1 CML: Potential diagnostic value and functional implications.

Sadovnik I, Herrmann H, Eisenwort G, Blatt K, Hoermann G, Mueller N Exp Hematol. 2017; 51:17-24.

PMID: 28457753 PMC: 6044418. DOI: 10.1016/j.exphem.2017.04.003.


Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects.

Culen M, Borsky M, Nemethova V, Razga F, Smejkal J, Jurcek T Oncotarget. 2016; 7(22):33016-24.

PMID: 27145281 PMC: 5078071. DOI: 10.18632/oncotarget.9108.